Puma Biotechnology Breakfast Product Theater:It’s Time to Give NERLYNX a Second Look: A Case-Based Discussion on Reducing Recurrence in HER2+ eBC1-3, (and Patient Experience) Brian Leyland Jones, MD, PhD (National Foundation for Cancer Research, Sioux Falls, SD) *
WELCOME to OCS 2023, Chuck Dukas, Master of Ceremonies and Host (Live Event Emcee, Warm-up, Auctioneer, Actor, and Host) *
Cancer Drug Update 2023, Teresa Knoop, MSN, RN, AOCN (Vanderbilt & ONS Board emerita) *
Managing Immune Related Adverse Events to Ensure Optimal Cancer Immunotherapy Outcomes: The Nurse’s View, Blanca Ledezma, MSN, NP-AOCNP (UCLA Health) *
Smarter. Stronger. Together. Optimizing Outcomes and an Equitable Healthcare Experience for All Patients with Gynecologic Cancers, Dana M. Chase, MD (UCLA) *
Efficacy and Safety of Asparaginase-Containing Treatment Regimens in ALL/LBL and
Beyond—An Interactive Review for Oncology Nurses and Nurse Practitioners,
Sandra Kurtin, PhD, ANP-C, AOCN (University of Arizona/Arizona Cancer Center) *
Exelixis Lunch Product Theater: A Combination Treatment for Patients with Advanced
Renal Cell Carcinoma, Nancy Moldawer, RN, MSN (Cedars-Sinai) *
Updates for Community Practice: Expert Guidance on Biomarker-Driven Therapeutic
Approaches in Gastrointestinal Cancers, Robert Lentz, MD (University of Colorado School of
Medicine & Cancer Center) *
Advances in Immunotherapy for Earlier Stages of Cancer: Guidance for Community
Multidisciplinary Teams, Heather McArthur, MD, MPH (UT Southwestern Medical Center) *

Updates in Metastatic Prostate Cancer Care: Expert Guidance for Multidisciplinary Community Practice and VHA Systems, Brenda Martone. MSN, ANP-BC, AOCNP (Northwestern Medicine)

Improving Outcomes for Patients with High-Risk, HR-Positive/HER2-Negative Early
Breast Cancer: Education and Resources for the Multidisciplinary Team, David B. Page, MD
(Providence Health & Services, Portland) *
Rate the posters as a group *
Rate the Learning Resource Center *
0/1000 characters
Powered byFormsite